Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)

PHASE2SuspendedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Heart DiseaseBlocked ArteriesCoronary IschemiaCoronary DiseaseCoronary Artery DiseaseCoronary Atherosclerosis
Interventions
BIOLOGICAL

MESENDO

For the cell product, proper aliquots of each cell type will be taken to fulfill the doses established for this protocol. The two aliquots will be mixed and resuspended to a final volume of 3 ml in the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin.

OTHER

placebo

For placebo, 3 ml of the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin will be transferred to a 5 ml syringe

Trial Locations (1)

70433

TCA Cellular Therapy, Covington

Sponsors
All Listed Sponsors
lead

TCA Cellular Therapy

INDUSTRY